Recombinant human PI3K (p110 delta/p85 alpha) protein (Active) (ab125633)

Overview

  • Product name

    Recombinant human PI3K (p110 delta/p85 alpha) protein (Active)
  • Protein length

    Full length protein

Description

  • Nature

    Recombinant
  • Source

    Baculovirus infected Sf9 cells
  • Amino Acid Sequence 1
    • Accession
    • Species

      Human
    • Molecular weight

      111 kDa
    • Amino acids

      1 to 1044
    • Tags

      His tag N-Terminus
    • Additional sequence information

      NM_005026.
    Amino Acid Sequence 2
    • Accession
    • Species

      Human
    • Molecular weight

      86 kDa
    • Amino acids

      2 to 724
    • Tags

      His tag N-Terminus
    • Additional sequence information

      NM_181253.

Specifications

Our Abpromise guarantee covers the use of ab125633 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity

    The specific activity of ab125633 was equivalent to 2,514 nmol/min/mg as per activity assay protocol.

  • Applications

    Western blot

    Functional Studies

    SDS-PAGE

  • Purity

    > 75 % Densitometry.

  • Form

    Liquid
  • Additional notes

    Kinase assay.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    pH: 7.00
    Preservative: 1.02% Imidazole
    Constituents: 0.002% PMSF, 0.82% Sodium phosphate, 0.004% DTT, 25% Glycerol, 1.74% Sodium chloride

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

Images

  • The specific activity of ab125633 was equivalent to 2,514 nmol/min/mg as per activity assay protocol.

  • Purity of ab125633 was determined to be >75% by densiometry.

References

This product has been referenced in:

  • Zhang H  et al. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett 15:9377-9384 (2018). Read more (PubMed: 29928334) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab125633.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up